Survival analysis anticipates the expected lifespans of individuals as well as the timing of other events. Learn about its pros and cons.
Outcomes with trilaciclib versus granulocyte colony stimulating factor regarding chemotherapy-associated adverse events, dose reductions, and subsequent therapies in small cell lung cancer. This is an ...
Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with renal cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results